AZD 3409

Drug Profile

AZD 3409

Alternative Names: AZD-3409; EBP-921; ZD-3409

Latest Information Update: 22 Dec 2015

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Eiger BioPharmaceuticals
  • Class Antineoplastics; Antivirals; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis D; Solid tumours

Most Recent Events

  • 22 Dec 2015 Discontinued - Phase-I for Hepatitis D in USA (PO)
  • 09 Jun 2005 Data presented at the 100th Annual Meeting of the American Urological Association (AUA-2005) have been added to the adverse events and Cancer pharmacodynamics sections
  • 14 Dec 2004 A clinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top